When a Sponsor chooses to engage with a contract research organization (CRO), the Sponsor team expects quality and performance in return for their investment. CROs are in business to conduct trials - and offload the work from the Sponsor’s side. So why are so many trials fraught with early hiccups? The
Kunal Sampat joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss the changing landscape of clinical trial operations. An experienced Clinical Operations Director, Kunal shares his key learnings from 2020 and elaborates on some of the successes and challenges he’s seen this year. Industry stakeholders
Most, if not all, industry events have gone virtual in 2020. Clinical Innovations Summit is the most recent one to convert to an online setting, and it's now combined with SCOPE Europe, usually held in beautiful Barcelona, Spain.
The ArcheMedX team is excited to be a cornerstone of this year's Clinical
Women of Color in Pharma (WOCIP) has emerged as a leading organization teaching our industry how to empower women of color through bold action.
Their value to all of us is best explained in their “Our Why” statement, where they commit to “Creating a nurturing and safe environment for self-reflection and
Choosing the right way to train clinical trial staff is complex and exhausting under normal circumstances. Today’s immense pressure to accommodate new virtual working styles across investigator meetings, site selection, and site initiation visits magnifies those challenges.
As we revealed in our recent report, clinical operations leaders are adopting virtual tools
Making it through the clinical trial start-up process is critical for any study - and takes a lot of effort under normal circumstances. But today, with the need to conduct more and more clinical operations remotely - it’s even more challenging.
The good news is that there is a way forward,
Getting new treatments approved has never been harder, but recent research reveals that the regulatory agency has also never been faster. So why is it getting more expensive and taking ever longer to bring a treatment to market? Three words: Clinical trial delays.
It’s taking longer to bring a treatment to